Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report

Xi Zhang, ErChang Shen, Chao Cheng, Rui Meng, Chao Liu, Qiang Shao · 2026

Read Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report by Xi Zhang, ErChang Shen, Chao Cheng, Rui Meng, Chao Liu, Qiang Shao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350766.txt.

Description

Xi Zhang and co-authors report a single bladder cancer case with a strong response to drug pairing in a 2026 paper. The patient, a man of eighty-three, had muscle-invasive bladder cancer and wanted to keep his bladder. Before surgery, he received three cycles of two drugs: an antibody-drug conjugate and an immune drug, given on a three-week cycle.

Side effects were limited to high blood sugar and a rash, both handled without stopping treatment. Scans afterward showed the mass largely gone, leaving only wall thickening. A scope procedure then sampled the bladder lining and found inflammation but no leftover cancer. The authors call it a favorable pathological response. They present bladder preservation in this selected patient as a workable path and a hypothesis for formal study.

Catalog record

CREATORXi Zhang, ErChang Shen, Chao Cheng, Rui Meng, Chao Liu, Qiang Shao
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE23 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13350766

Browse the full library · About the Tower of Babel